---
title: "Neurol-Oncology 2025 | CAF靶点LRRC15-与M2互作-增效免疫治疗"
date: 2025-07-06T08:31:45Z
draft: ["false"]
tags: [
  "fetched",
  "NeuroLab Precision"
]
categories: ["Acdemic"]
---
Neurol-Oncology 2025 | CAF靶点LRRC15-与M2互作-增效免疫治疗 by NeuroLab Precision
------
<div><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibWOm6WR8KeWlrKA5QoP0hJQKRdDwenoZCcqKgEfkaDXxH91hcyViaIQg/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.40106382978723404" data-s="300,640" data-type="png" data-w="940" type="block" data-imgfileid="100001164" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibWOm6WR8KeWlrKA5QoP0hJQKRdDwenoZCcqKgEfkaDXxH91hcyViaIQg/640?wx_fmt=png&amp;from=appmsg"></section><p data-pm-slice="0 0 []"><span leaf=""><span textstyle="">本次分享的文章于2025年6月发表在 </span><span textstyle="">Neurol-Oncology（Q1/1区，IF 13.4）</span><span textstyle="">，题目为“</span></span><strong><span leaf=""><span textstyle="">CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma</span></span></strong><span leaf=""><span textstyle="">”，由广东省人民医院领衔，通过单细胞测序发现LRRC15+ CAFs亚群在PD-1耐药患者中富集，进而利用基因编辑、多组学分析和动物模型证实：LRRC15通过FAK-SRC-NF-κB轴促进IL8分泌，诱导M2型巨噬细胞极化；同时M2巨噬细胞分泌TGF-β1通过SMAD2反馈激活CAFs中LRRC15表达，形成促瘤正反馈循环。最后证实靶向LRRC15可增强PD-1治疗效果，为联合免疫治疗提供新策略。</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibmVWiaLUDWUt2vhSZwfFTja8NL8rNUkTQypM3Fnl7G20BLVdn95X4ibJQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.6038251366120219" data-s="300,640" data-type="png" data-w="732" type="block" data-imgfileid="100001165" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibmVWiaLUDWUt2vhSZwfFTja8NL8rNUkTQypM3Fnl7G20BLVdn95X4ibJQ/640?wx_fmt=png&amp;from=appmsg"></section><p><strong><span leaf=""><span textstyle="">Introduction</span></span></strong></p><ol><li><section><strong><span leaf=""><span textstyle="">临床问题</span></span></strong><span leaf=""><span textstyle="">：胶质母细胞瘤（GBM）恶性程度高，患者生存期短（中位15个月），现有治疗（包括免疫检查点阻断疗法ICB）效果有限，亟需克服耐药性。</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">耐药机制的核心</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li></ol><ul><li><section><span leaf=""><span textstyle="">Mφ的M2型极化促进免疫抑制，与不良预后相关。</span></span></section></li><li><section><span leaf=""><span textstyle="">CAFs（尤其间质亚型GBM中）通过标志物（如FAP）抑制免疫，且抗PD-1治疗会富集CAFs和M2型Mφ，加剧耐药。</span></span></section></li></ul><ul><li><section><span leaf=""><span textstyle="">肿瘤免疫抑制微环境（TIME）是耐药关键，其中</span></span><strong><span leaf=""><span textstyle="">巨噬细胞（Mφ）和癌症相关成纤维细胞（CAFs）</span></span></strong><span leaf=""><span textstyle=""> 是主要调控者：</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">研究空白</span></span></strong><span leaf=""><span textstyle="">：CAFs在GBM中的起源、作用及标志物（如新发现的LRRC15）机制不明</span></span></section></li><p><span leaf=""><span textstyle="">Results</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribk71SAgE5tGKWW7n6mczxs7xLH1KpnkQiaDtSm1clFQic7RIBO0mKqa0w/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.55" data-s="300,640" data-type="png" data-w="800" type="block" data-imgfileid="100001166" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribk71SAgE5tGKWW7n6mczxs7xLH1KpnkQiaDtSm1clFQic7RIBO0mKqa0w/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><span textstyle="">图 1.LRRC15 表达上调的 CAFs 群体在抗 PD-1 无反应 GBM 中富集，并与 Mφ 极化呈正相关</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribfd8gMjggia9bPrQrql0HjDQLa0n3rBgOaicZ3IbeHM1FJTIWGUHOTZ2g/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.738031914893617" data-s="300,640" data-type="png" data-w="752" type="block" data-imgfileid="100001167" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribfd8gMjggia9bPrQrql0HjDQLa0n3rBgOaicZ3IbeHM1FJTIWGUHOTZ2g/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibBow4Nicncvbde6LKHP81ibCOD9MokgN9LrsIh2muuHkdfBdIBpyibKP3g/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.8156028368794326" data-s="300,640" data-type="png" data-w="846" type="block" data-imgfileid="100001168" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibBow4Nicncvbde6LKHP81ibCOD9MokgN9LrsIh2muuHkdfBdIBpyibKP3g/640?wx_fmt=png&amp;from=appmsg"></section><h4><span><strong><span leaf=""><span textstyle="">1. CAF亚群鉴定</span></span></strong></span></h4><ul><li><section><span leaf=""><span textstyle="">通过scRNA-seq和stRNA-seq分析GBM样本，鉴定出</span></span><strong><span leaf=""><span textstyle="">4种CAF亚群</span></span></strong><span leaf=""><span textstyle="">（图1A-D）：</span></span></section></li><ul><li><section><strong><span leaf=""><span textstyle="">MyoCAFs（C1）</span></span></strong><span leaf=""><span textstyle="">：高表达</span></span><strong><span leaf=""><span textstyle="">ACTA2</span></span></strong><span leaf=""><span textstyle="">和</span></span><strong><span leaf=""><span textstyle="">LRRC15</span></span></strong><span leaf=""><span textstyle="">（关键标志物），富集于间质型GBM。</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">ProCAFs（C2）</span></span></strong><span leaf=""><span textstyle="">、</span></span><strong><span leaf=""><span textstyle="">MatCAFs（C3）</span></span></strong><span leaf=""><span textstyle="">、</span></span><strong><span leaf=""><span textstyle="">iCAFs（C4）</span></span></strong><span leaf=""><span textstyle="">：各有独特标志基因（如COL3A1、CCL2等）。</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">MyoCAFs</span></span></strong><span leaf=""><span textstyle="">在</span></span><strong><span leaf=""><span textstyle="">PD-1非响应组</span></span></strong><span leaf=""><span textstyle="">中占比最高（图1E），提示其与免疫抑制相关。</span></span></section></li></ul><h4><span><strong><span leaf=""><span textstyle="">2. LRRC15与PD-1耐药的关联</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">LRRC15</span></span></strong><span leaf=""><span textstyle="">在非响应组CAF中显著高表达（图1F-G），且在多个ICB研究数据库（ICBatlas、Zhao/Yang队列）中验证（补充图1D）。</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">LRRC15</span></span></strong><span leaf=""><span textstyle="">主要表达于CAF（图1H），且与</span></span><strong><span leaf=""><span textstyle="">细胞因子-受体互作通路</span></span></strong><span leaf=""><span textstyle="">（KEGG）和</span></span><strong><span leaf=""><span textstyle="">CXCL信号</span></span></strong><span leaf=""><span textstyle="">（CellChat分析）相关，暗示CAF与Mφ的通讯（图1I）。</span></span></section></li></ul><h4><span><strong><span leaf=""><span textstyle="">3. LRRC15与M2型Mφ的关联</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">TCGA数据</span></span></strong><span leaf=""><span textstyle="">显示：LRRC15与</span></span><strong><span leaf=""><span textstyle="">M2型Mφ</span></span></strong><span leaf=""><span textstyle="">、耗竭T细胞特征正相关（补充图2B-C）。</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">空间转录组（stRNA）和</span></span></strong><span leaf=""><span textstyle="">多重免疫荧光证实：LRRC15+ CAF与</span></span><strong><span leaf=""><span textstyle="">CD68+CD206+ Mφ</span></span></strong><span leaf=""><span textstyle="">共定位（图1J，补充图2D）。</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">临床意义</span></span></strong><span leaf=""><span textstyle="">：LRRC15高表达与GBM患者不良预后显著相关（补充图2F-H）。</span></span></section></li></ul><h4><span><strong><span leaf=""><span textstyle="">核心结论：LRRC15+ MyoCAFs</span></span></strong><span leaf=""><span textstyle="">是PD-1耐药GBM中的关键免疫抑制CAF亚群，通过调控Mφ向M2型极化促进耐药。</span></span></span></h4><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibAz1LEEowD4PrZ8H7Npp1C1QWnEOZr2jK00z1n4RGLibibpddVRUhRFoQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.5693527080581242" data-s="300,640" data-type="png" data-w="757" type="block" data-imgfileid="100001169" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibAz1LEEowD4PrZ8H7Npp1C1QWnEOZr2jK00z1n4RGLibibpddVRUhRFoQ/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><span textstyle="">图 2.CAFs 中 LRRC15 的基因消融在体外和体内抑制 Mφs 免疫抑制</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibSmV2MqLhdMzrEuZ2iaTKgpicHibWuV4ocqlaNGicxhBVQeV3g0xcDoDOrA/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.0406091370558375" data-s="300,640" data-type="png" data-w="788" type="block" data-imgfileid="100001170" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibSmV2MqLhdMzrEuZ2iaTKgpicHibWuV4ocqlaNGicxhBVQeV3g0xcDoDOrA/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibmKBmiczOkdDp6qIQm2OnErTLO4OauaLtbzqWAgEvSaKl3bVOKsrPQpw/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.6670702179176755" data-s="300,640" data-type="png" data-w="826" type="block" data-imgfileid="100001171" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibmKBmiczOkdDp6qIQm2OnErTLO4OauaLtbzqWAgEvSaKl3bVOKsrPQpw/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibTbTNzgUdicbRFEYfaJe5u2GPHuS48GwntnFYB1ICUr98QtJcjd59h5Q/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.7841059602649006" data-s="300,640" data-type="png" data-w="755" type="block" data-imgfileid="100001172" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibTbTNzgUdicbRFEYfaJe5u2GPHuS48GwntnFYB1ICUr98QtJcjd59h5Q/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibP1xdo6iabwpauD6h8SdHicNF1e7XrQlb9pEYic5PDQx0kNbSjQ1gJNmTA/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.064327485380117" data-s="300,640" data-type="png" data-w="855" type="block" data-imgfileid="100001173" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibP1xdo6iabwpauD6h8SdHicNF1e7XrQlb9pEYic5PDQx0kNbSjQ1gJNmTA/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibeayXeOoCfwmwELXIlREWJRmxtDyATxwibjYUN8lW51pAsBIeHQpxrjA/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.846242774566474" data-s="300,640" data-type="png" data-w="865" type="block" data-imgfileid="100001174" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibeayXeOoCfwmwELXIlREWJRmxtDyATxwibjYUN8lW51pAsBIeHQpxrjA/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibpRVjYGmu9DFhCEWdzHSMicRfmMgI6ibZKSM0Je1gSYibtHtxIEM5icC0yA/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.1388564760793465" data-s="300,640" data-type="png" data-w="857" type="block" data-imgfileid="100001175" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibpRVjYGmu9DFhCEWdzHSMicRfmMgI6ibZKSM0Je1gSYibtHtxIEM5icC0yA/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib4nohyeBNHoVWXPYzMibSiaPRVw8iakqC1S9ViblJQBOeYnBy6AmQkHbQgQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.260115606936416" data-s="300,640" data-type="png" data-w="865" type="block" data-imgfileid="100001176" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib4nohyeBNHoVWXPYzMibSiaPRVw8iakqC1S9ViblJQBOeYnBy6AmQkHbQgQ/640?wx_fmt=png&amp;from=appmsg"></section><h4><span><strong><span leaf=""><span textstyle="">1. LRRC15调控Mφ极化的双向验证</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">体外实验</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><strong><span leaf=""><span textstyle="">敲除LRRC15</span></span></strong><span leaf=""><span textstyle="">：显著抑制CAF诱导的M2型Mφ极化（CD206等标志物↓，图2A-B）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">过表达LRRC15</span></span></strong><span leaf=""><span textstyle="">：促进M2型极化并增强Mφ迁移能力（图2C，补充图4A-B）</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">体内模型</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">CD8+ T细胞浸润↑，耗竭标志物↓（图2E-F）</span></span></section></li><li><section><span leaf=""><span textstyle="">M2型Mφ比例↓（流式/免疫荧光验证）</span></span></section></li><li><section><span leaf=""><span textstyle="">T细胞活化标志物（IFNG、Ki67）表达↑（图2G）</span></span></section></li></ul><ul><li><section><span leaf=""><span textstyle="">特异性敲除CAFs中的Lrrc15（非内皮细胞，补充图5-6）</span></span></section></li><li><section><span leaf=""><span textstyle="">导致肿瘤微环境显著改变：</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">2. 分子机制深度解析</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">单细胞转录组证据</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">Mφ高表达抗肿瘤基因（Isg15、Cxcl9等）</span></span></section></li><li><section><span leaf=""><span textstyle="">T细胞高表达干扰素相关基因（Ifng、Ifitm3）（图2H-I）</span></span></section></li></ul><ul><li><section><span leaf=""><span textstyle="">Lrrc15⁻/⁻肿瘤中：</span></span></section></li><li><section><span leaf=""><span textstyle="">信号通路富集于T细胞活化相关通路（补充图8）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">3. 治疗效应验证</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">肿瘤生长抑制</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">在两种GBM模型（GL261/CT2A）中均显著抑制肿瘤生长（图2J，补充图9A-C）</span></span></section></li><li><section><span leaf=""><span textstyle="">生存期显著延长（图2J）</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">机制依赖性验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">使用抗CSF1R抗体清除Mφ后：Lrrc15敲除的抗肿瘤效应完全消失（补充图9D-F）</span></span></section></li><li><section><span leaf=""><span textstyle="">LRRC15的抗肿瘤作用完全依赖于Mφ的存在</span></span></section></li></ul></ul><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribfia7icVl5piaOGu8Oo2FxYTDoPLkiavjbcTkhn0EDU5Kfan78hd2R80p8g/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.1074197120708749" data-s="300,640" data-type="png" data-w="903" type="block" data-imgfileid="100001178" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribfia7icVl5piaOGu8Oo2FxYTDoPLkiavjbcTkhn0EDU5Kfan78hd2R80p8g/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><span textstyle="">图 3.CAF 中的 LRRC15 通过 I</span></span><span leaf=""><span textstyle="">L</span></span><span leaf=""><span textstyle="">8 促进替代 Mφ 极化</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribd7vlgqVC767siauS5hC5fRhXgKnkM5ibsoOGA05hqiaBySteV6OibGqsbA/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.2323699421965317" data-s="300,640" data-type="png" data-w="865" type="block" data-imgfileid="100001179" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Ribd7vlgqVC767siauS5hC5fRhXgKnkM5ibsoOGA05hqiaBySteV6OibGqsbA/640?wx_fmt=png&amp;from=appmsg"></section><h4><span><strong><span leaf=""><span textstyle="">1. 关键发现</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">LRRC15调控IL8分泌</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">LRRC15敲除CAFs中IL8显著减少（图3A-B，补充图10A）。</span></span></section></li><li><section><span leaf=""><span textstyle="">LRRC15过表达CAFs中IL8 mRNA和蛋白水平上升（图3C-E，补充图10B-E）。</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">2. IL8与M2极化的关系</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">正相关性</span></span></strong><span leaf=""><span textstyle="">：IL8与LRRC15、M2标志物CD206表达呈正相关（图3D，补充图10C）。</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">功能验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">敲低IL8可阻断LRRC15过表达诱导的Mφ迁移和CD206表达（图3F-G，补充图10F-G）。</span></span></section></li><li><section><span leaf=""><span textstyle="">外源IL8直接促进Mφ迁移及M2标志物（CD206/TGF-β）和STAT6磷酸化（图3H，补充图10H）。</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">3. 核心结论：LRRC15（CAFs）→ IL8↑ → Mφ迁移&amp;M2极化（依赖STAT6）→ 促肿瘤免疫微环境</span></span></strong></span></h4><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib0Cb9sibwdr2IxlvahMk1C733F1RTNL3iaUXicniaULTcQGzUtT1xsBtAjw/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.167741935483871" data-s="300,640" data-type="png" data-w="930" type="block" data-imgfileid="100001180" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib0Cb9sibwdr2IxlvahMk1C733F1RTNL3iaUXicniaULTcQGzUtT1xsBtAjw/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><span textstyle="">图 4.LRRC15 通过激活 FAK-SRC NF-κB 通路调节 CAFs 中 IL8 的表达</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibfeTv9icmYfiblvTge3kD4txwLchcZXAicQooAgbBrM3tA7RATMPQjLRYQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.6285046728971962" data-s="300,640" data-type="png" data-w="856" type="block" data-imgfileid="100001181" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibfeTv9icmYfiblvTge3kD4txwLchcZXAicQooAgbBrM3tA7RATMPQjLRYQ/640?wx_fmt=png&amp;from=appmsg"></section><h4><span><strong><span leaf=""><span textstyle="">1. 通路发现</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">NF-κB信号激活</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">单细胞测序显示CAFs中NF-κB通路活化（图4A）</span></span></section></li><li><section><span leaf=""><span textstyle="">TCGA数据证实LRRC15与炎症抑制信号（CD163）相关（图4B）</span></span></section></li><li><section><span leaf=""><span textstyle="">转录组分析显示LRRC15过表达激活整合素/NF-κB通路（图4C-D）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">2. 关键磷酸化验证</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">LRRC15调控磷酸化级联</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">LRRC15敲除→FAK/SRC/P65磷酸化↓</span></span></section></li><li><section><span leaf=""><span textstyle="">外源LRRC15补充→磷酸化恢复（图4E）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">3. 药物干预验证</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">通路抑制剂逆转效应</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">LRRC15过表达诱导的IL8分泌（图4F）</span></span></section></li><li><section><span leaf=""><span textstyle="">M2标志物表达及Mφ迁移能力（图4G-H，补充图11A-C）</span></span></section></li></ul><ul><li><section><span leaf=""><span textstyle="">FAK/SRC/NF-κB抑制剂（PF573228/PP2/CAPE）显著降低：</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">4. 核心结论：LRRC15 → FAK-SRC-NF-κB磷酸化 → IL8分泌↑ → M2型巨噬细胞极化</span></span></strong></span></h4><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibianmkvavCLM3n6iaSUvrOHS2qdGjLSzWGxCVe5pJPt55iaWNGSlaoPkicQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.0714285714285714" data-s="300,640" data-type="png" data-w="924" type="block" data-imgfileid="100001184" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibianmkvavCLM3n6iaSUvrOHS2qdGjLSzWGxCVe5pJPt55iaWNGSlaoPkicQ/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><span textstyle="">图 5.M2 样 Mφ 来源的 TGF-β1 通过 SMAD2 驱动的转录激活促进 LRRC15 在 CAF 中的表达</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibM6a5SCeHm1ficS4Nvm76FpdKtUYqIhicWKMfP3sz96ea38foRhK6NprA/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.424198250728863" data-s="300,640" data-type="png" data-w="686" type="block" data-imgfileid="100001185" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6RibM6a5SCeHm1ficS4Nvm76FpdKtUYqIhicWKMfP3sz96ea38foRhK6NprA/640?wx_fmt=png&amp;from=appmsg"></section><h4><span><strong><span leaf=""><span textstyle="">1. TGF-β1诱导LRRC15表达</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">数据支持</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">单细胞测序显示Mφ高表达TGFB1（补充图12A）</span></span></section></li><li><section><span leaf=""><span textstyle="">外源TGF-β1刺激可剂量依赖性上调LRRC15（图5A）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">2. 关键转录因子筛选</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">数据库预测</span></span></strong><span leaf=""><span textstyle="">：SMAD2、RUNX1、ESR1可能调控LRRC15（图5B，补充图12B）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">实验验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">仅SMAD2敲低能显著减少LRRC15表达（补充图12D-F）</span></span></section></li><li><section><span leaf=""><span textstyle="">TCGA数据证实LRRC15与SMAD2正相关（图5C）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">3. SMAD2磷酸化与DNA结合</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">TGF-β1激活SMAD2</span></span></strong><span leaf=""><span textstyle="">：磷酸化水平呈时间/剂量依赖性升高（图5D-E）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">结合位点鉴定</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">LRRC15启动子区存在2个SMAD2结合位点（图5F，补充图12G）</span></span></section></li><li><section><span leaf=""><span textstyle="">ChIP-qPCR证实p-SMAD2富集于结合位点1（图5G）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">4. 转录激活验证</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">荧光素酶报告实验</span></span></strong><span leaf=""><span textstyle="">：突变"TGACTCA"核心序列（结合位点1/2）可阻断TGF-β1诱导的LRRC15转录激活（图5H-K）</span></span></section></li></ul><h4><span><strong><span leaf=""><span textstyle="">5. 核心结论：M2型Mφ → TGF-β1分泌 → SMAD2磷酸化 → 结合LRRC15启动子 → LRRC15表达↑ → 进一步促进M2极化</span></span></strong></span></h4><figure><span leaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib6IxDfFvJXcVRJo9JTGgcOfDq8Gyx50dqBPGaYGFqzGc6Uibyic7HZu8Q/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.4493670886075949" data-s="300,640" data-type="png" data-w="790" type="block" data-imgfileid="100001182" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib6IxDfFvJXcVRJo9JTGgcOfDq8Gyx50dqBPGaYGFqzGc6Uibyic7HZu8Q/640?wx_fmt=png&amp;from=appmsg"></span></figure><p><span leaf=""><span textstyle="">图 6.LRRC15 阻断使 GBM 对 PD-1 免疫疗法敏感</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib1ACGxiciaWf9ib2zCaFiaSfqULDAyaAGKysicE8mVlJicItz49pkBxPZRyEA/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.7307692307692308" data-s="300,640" data-type="png" data-w="650" type="block" data-imgfileid="100001186" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib1ACGxiciaWf9ib2zCaFiaSfqULDAyaAGKysicE8mVlJicItz49pkBxPZRyEA/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib63TqGdyjKZZLQVibTpm27UfKuZy7Sy9odDoCemsmP2KB1FOrxSTBRXw/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.6504629629629629" data-s="300,640" data-type="png" data-w="864" type="block" data-imgfileid="100001187" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJTRpCAT5QeAKib1EYtm9u6Rib63TqGdyjKZZLQVibTpm27UfKuZy7Sy9odDoCemsmP2KB1FOrxSTBRXw/640?wx_fmt=png&amp;from=appmsg"></section><h4><span><strong><span leaf=""><span textstyle="">1. 抗LRRC15抗体的体外验证</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">作用机制</span></span></strong><span leaf=""><span textstyle="">：αLRRC15抗体处理显著抑制M2型巨噬细胞极化（流式/qPCR验证，补充图13A-B）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">关键数据</span></span></strong><span leaf=""><span textstyle="">：Lrrc15过表达条件培养基（OE-CM）诱导的M2极化可被αLRRC15抗体逆转</span></span></section></li></ul><h4><span><strong><span leaf=""><span textstyle="">2. 单药治疗效果</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">体内抗肿瘤效应</span></span></strong><span leaf=""><span textstyle="">：αLRRC15单药显著抑制GL261肿瘤生长（图6A）并延长生存期（图6B，补充图13C）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">免疫微环境改变</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">M2型巨噬细胞（F4/80⁺CD206⁺）↓</span></span></section></li><li><section><span leaf=""><span textstyle="">CD8⁺ T细胞浸润↑，耗竭标志物↓，增殖（Ki67）与功能（IFNG）↑（补充图13D-J）</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">3. 联合PD-1阻断的协同效应</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">显著增强疗效</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">在GL261和CT2A模型中，联合治疗比单药更有效抑制肿瘤（补充图14A-D）</span></span></section></li><li><section><span leaf=""><span textstyle="">生存期显著优于单药组（图6C-D，补充图14E-G）</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">机制特征</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">协同增强CD8⁺ T细胞浸润（图6E）</span></span></section></li><li><section><span leaf=""><span textstyle="">同时减少M2巨噬细胞积累和T细胞耗竭</span></span></section></li></ul></ul><p><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"box-sizing: border-box; margin: 0px; font-size: 16px; padding-top: 8px; padding-bottom: 8px; line-height: 1.5em; color: rgb(0, 0, 0); font-family: Optima-Regular, Optima, PingFangSC-light, PingFangTC-light, \"PingFang SC\", Cambria, Cochin, Georgia, Times, \"Times New Roman\", serif; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">Methods</span></span></p><h4><span><strong><span leaf=""><span textstyle="">1. 科学问题提出</span></span></strong></span></h4><ul><li><section><strong><span leaf=""><span textstyle="">临床现象</span></span></strong><span leaf=""><span textstyle="">：</span></span><span leaf=""><span textstyle="">GBM对PD-1/PD-L1治疗耐药</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">关键缺口</span></span></strong><span leaf=""><span textstyle="">：CAFs和Mφ在TIME中如何协同介导耐药？LRRC15是否参与调控？</span></span></section></li></ul><p><strong><span leaf=""><span textstyle="">假设</span></span></strong><span leaf=""><span textstyle="">：LRRC15+ CAFs通过调控Mφ极化驱动免疫抑制微环境，导致PD-1耐药。</span></span></p><h4><span><strong><span leaf=""><span textstyle="">2. 研究逻辑与实验设计</span></span></strong></span></h4><h5><span><strong><span leaf=""><span textstyle="">阶段一：发现LRRC15+ CAF亚群与PD-1耐药的关联</span></span></strong></span></h5><ul><li><section><strong><span leaf=""><span textstyle="">数据挖</span></span></strong><strong><span leaf=""><span textstyle="">掘</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">对已发表的scRNA-seq/stRNA-seq数据再分析（24例GBM样本）</span></span></section></li><li><section><span leaf=""><span textstyle="">鉴定CAF亚群（MyoCAFs/ProCAFs/MatCAFs/iCAFs），聚焦LRRC15+ MyoCAFs</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">临床验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">对比PD-1响应 vs. 非响应组中LRRC15表达（IHC、TCGA数据）</span></span></section></li><li><section><span leaf=""><span textstyle="">生存分析（LRRC15高表达与预后差的相关性）</span></span></section></li></ul></ul><h5><span><strong><span leaf=""><span textstyle="">阶段二：验证LRRC15的功能机制</span></span></strong></span></h5><ul><li><section><strong><span leaf=""><span textstyle="">体外模型</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><strong><span leaf=""><span textstyle="">基因操作</span></span></strong><span leaf=""><span textstyle="">：CRISPR敲除/过表达LRRC15（CAFs）→ 检测Mφ极化标志物（CD206/TGF-β）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">细胞互作</span></span></strong><span leaf=""><span textstyle="">：CAF-Mφ共培养体系，检测迁移（Transwell）和极化（流式/qPCR）</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">体内模型</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><strong><span leaf=""><span textstyle="">转基因小鼠</span></span></strong><span leaf=""><span textstyle="">：Lrrc15⁻/⁻小鼠构建原位GBM（GL261/CT2A）</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">免疫表型分析</span></span></strong><span leaf=""><span textstyle="">：流式检测CD8+ T细胞/M2-Mφ比例，scRNA-seq解析微环境变化</span></span></section></li></ul></ul><h5><span><strong><span leaf=""><span textstyle="">阶段三：解析LRRC15下游信号通路</span></span></strong></span></h5><ul><li><section><strong><span leaf=""><span textstyle="">分子机制</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">磷酸化检测（FAK/SRC/NF-κB）</span></span></section></li><li><section><span leaf=""><span textstyle="">药理学抑制（FAK/SRC/NF-κB抑制剂逆转实验）</span></span></section></li></ul><ul><li><section><strong><span leaf=""><span textstyle="">分泌组筛选</span></span></strong><span leaf=""><span textstyle="">：LRRC15敲除CAFs的细胞因子阵列→ 锁定IL8</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">通路验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">转录调控</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">ChIP-qPCR验证SMAD2结合LRRC15启动子</span></span></section></li><li><section><span leaf=""><span textstyle="">荧光素酶报告实验（突变结合位点）</span></span></section></li></ul><ul><li><section><strong><span leaf=""><span textstyle="">TGF-β/SMAD2反馈环路</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li></ul></ul><h5><span><strong><span leaf=""><span textstyle="">阶段四：治疗策略开发</span></span></strong></span></h5><ul><li><section><strong><span leaf=""><span textstyle="">抗体干预</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">αLRRC15单药治疗（原位/皮下模型）</span></span></section></li><li><section><span leaf=""><span textstyle="">联合αPD-1的协同效应验证（生存期、免疫细胞浸润）</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">机制依赖性验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">抗CSF1R抗体清除Mφ，观察LRRC15敲除效应是否消失</span></span></section></li></ul></ul><h4><span><strong><span leaf=""><span textstyle="">3. 实验设计亮点</span></span></strong></span></h4><ol><li><section><strong><span leaf=""><span textstyle="">多组学交叉验证</span></span></strong><span leaf=""><span textstyle="">：单细胞转录组+空间转录组+TCGA数据</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">因果链完整</span></span></strong><span leaf=""><span textstyle="">：基因操作（CRISPR/OE）→ 表型验证 → 通路解析 → 治疗干预</span></span></section></li><li><section><strong><span leaf=""><span textstyle="">双模型验证</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li></ol><ul><li><section><span leaf=""><span textstyle="">免疫原性不同模型（GL261 vs. CT2A）</span></span></section></li><li><section><span leaf=""><span textstyle="">原位+皮下肿瘤模型</span></span></section></li></ul><li><section><strong><span leaf=""><span textstyle="">正交实验设计</span></span></strong><span leaf=""><span textstyle="">：</span></span></section></li><ul><li><section><span leaf=""><span textstyle="">体外共培养+体内转基因动物</span></span></section></li><li><section><span leaf=""><span textstyle="">药理学抑制+遗传学敲除</span></span></section></li></ul><h4><span><strong><span leaf=""><span textstyle="">4. 逻辑推进图示</span></span></strong></span></h4><p><strong><span leaf=""><span textstyle="">临床问题</span></span></strong><span leaf=""><span textstyle=""> → </span></span><strong><span leaf=""><span textstyle="">CAF异质性分析</span></span></strong><span leaf=""><span textstyle=""> → </span></span><strong><span leaf=""><span textstyle="">LRRC15功能验证</span></span></strong><span leaf=""><span textstyle=""> → </span></span><strong><span leaf=""><span textstyle="">IL8/FAK-SRC-NF-κB通路</span></span></strong><span leaf=""><span textstyle=""> → </span></span><strong><span leaf=""><span textstyle="">TGF-β/SMAD2反馈环路</span></span></strong><span leaf=""><span textstyle=""> → </span></span><strong><span leaf=""><span textstyle="">抗体联合治疗</span></span></strong></p><p><span leaf=""><span textstyle="">Reference</span></span></p><p><span leaf=""><span textstyle="">Feifei Luo, Yan Mei, Yanwen Li, Jiahao Yang, Shaoyan Xi, Endong Cao, Cong Shen, Dexiang Zhou, Peng Wang, Dong Zhou, Haiping Cai, CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma, </span></span><em><span leaf=""><span textstyle="">Neuro-Oncology</span></span></em><span leaf=""><span textstyle="">, 2025, noaf157,doi.org/10.1093/neuonc/noaf157</span></span></p><section><span leaf=""><br></span></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/ituBkm4Y9uR2T58mujn9sw",target="_blank" rel="noopener noreferrer">原文链接</a>
